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synergizes with bacterial efflux 
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susceptibility to antibiotics in 
multi-drug resistant Pseudomonas 
aeruginosa strains
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susana sánchez-Gómez6 & Guillermo Martínez-de-tejada  1,2
Resistance to antibiotics poses a major global threat according to the World Health Organization. 
Restoring the activity of existing drugs is an attractive alternative to address this challenge. One of 
the most efficient mechanisms of bacterial resistance involves the expression of efflux pump systems 
capable of expelling antibiotics from the cell. Although there are efflux pump inhibitors (EPIs) available, 
these molecules are toxic for humans. We hypothesized that permeability-increasing antimicrobial 
peptides (AMPs) could lower the amount of EPI necessary to sensitize bacteria to antibiotics that 
are efflux substrates. To test this hypothesis, we measured the ability of polymyxin B nonapeptide 
(PMBN), to synergize with antibiotics in the presence of EPIs. Assays were performed using planktonic 
and biofilm-forming cells of Pseudomonas aeruginosa strains overexpressing the MexAB-OprM efflux 
system. Synergy between PMBN and EPIs boosted azithromycin activity by a factor of 2,133 and 
sensitized P. aeruginosa to all tested antibiotics. This reduced several orders of magnitude the amount 
of inhibitor needed for antibiotic sensitization. The selected antibiotic-EPI-PMBN combination caused 
a 10 million-fold reduction in the viability of biofilm forming cells. We proved that AMPs can synergize 
with EPIs and that this phenomenon can be exploited to sensitize bacteria to antibiotics.
At the beginning of 2017, the World Health Organization issued for the first time in its history a global priority 
list of antibiotic-resistant bacteria1. This list included the 12 pathogens that pose the greatest threat to human 
health and its objective was to help in prioritizing the research and development of new antibiotic treatments. In 
particular, the document warned about the emergence of gram-negative pathogens that are resistant to multiple 
antibiotics, being carbapenem-resistant P. aeruginosa considered one of the critical priorities.
P. aeruginosa possesses both intrinsic and adaptive resistance to a wide variety of antimicrobials and fre-
quently causes bacteremia, healthcare related pneumonia and urinary tract infections2. This organism is the 
most common bacterial species infecting the respiratory tract in cystic fibrosis patients3. The intrinsic mecha-
nisms of resistance of P. aeruginosa include the low permeability of its outer membrane and the expression of 
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numerous efflux systems that pump antibiotics out of the cell4,5. In addition, P. aeruginosa readily forms biofilms, 
surface-associated microbial communities that are extremely tolerant to antibiotics and immune system effec-
tors. The ability of P. aeruginosa cells to form biofilms during infection facilitates its persistence inside the host6. 
Finally, P. aeruginosa rapidly develops resistance during anti-pseudomonal chemotherapy through overexpres-
sion of efflux pumps, loss of porins, alteration of drug targets or enzymatic modification of antibiotics.
Between 1940 and 1962, more than 20 different types of antibiotics were approved, whereas only 2 new classes 
of these drugs reached the market in the following 48 years7. As of May 2017, only 5 out of 33 antibiotics that are 
being developed for priority pathogens can be considered as novel agents8. Therefore, to control the continuous 
expansion of antimicrobial resistance, restoring the activity of existing antibiotics appears of critical importance.
Efflux pump activity contributes to reduced antibiotic susceptibility in both planktonic and biofilm cells9–11. P. 
aeruginosa has 12 resistance-nodulation-division (RND)-type efflux systems, being MexAB-OprM the best char-
acterized4. This pump is constitutively expressed and exhibits an incredibly high ability to capture and extrude 
very structurally different antimicrobials including β-lactams, fluoroquinolones, macrolides, tetracyclines, tri-
methoprim, sulfamides and chloramphenicol12. The deletion of some regulatory genes such as mexR, nalD and 
nalC derepresses the system, thereby increasing bacterial resistance to its substrates13.
Two of the best characterized efflux pump inhibitors (EPIs) for Gram-negative bacteria are PAβN 
(Phenylalanine-Arginine β-Naphthylamide) and NMP (1-(1-naphthylmethyl)-piperazine)14,15. PAβN is a broad 
spectrum inhibitor of MexAB-OprM, MexCD-OprJ, and MexEF-OprN in P. aeruginosa and AcrABTolC in E. 
coli15,16. This EPI behaves itself as a substrate of efflux pumps binding in all likelihood to the transporter domain 
of these systems (the protein MexB in the case of MexAB-OprM)15,17. NMP is also a substrate of efflux pumps, 
although this EPI shows a pattern of antibiotic enhancing activity different from that of PAβN15,18.
Unfortunately, at high concentrations these and other EPIs are toxic to human cells and this fact hampered 
their clinical development up to now15.
We hypothesized that a possible way to decrease EPIs toxicity would be to co-administer them along with 
a membrane permeabilizing antimicrobial peptide (AMP). One of the most potent permeabilizers of this class 
for Gram-negative bacteria is polymyxin B nonapeptide (PMBN), a papain-cleaved derivative of polymyxin B 
(PMB)19. Interestingly, PMBN has an acute toxicity in mice of 43 mg/kg, almost five times lower than that of its 
parent compound, PMB, which is in clinical use20. Recently, PMBN was reported to be much less nephrotoxic 
than polymyxin E (colistin) and PMB in rats21,22.
PMBN has been shown to sensitize bacteria to antibiotics and here we investigated whether it also exhibits 
EPI-enhancing activity against planktonic and biofilm forming cells of P. aeruginosa23–25.
Results
Characterization of strains. We selected two P. aeruginosa strains that overexpress MexAB-OprM, namely 
LC1-6, a nalB mutant derivative of the wild type PAO1 strain26, and Ps4, a multidrug resistant clinical isolate 
previously characterized by our group24. As controls, we used two P. aeruginosa strains that do not overexpress 
MexAB-OprM, the wild type PAO1 and K111927, a PAO1 derivate with a deletion in the efflux pump MexAB-
OprM that abrogates its activity. To further characterize those strains, we determined the MIC of several antibiot-
ics that had previously been described as substrates of the MexAB-OprM pump such as penicillins (piperacillin, 
amoxicillin, ampicillin and ticarcillin), third generation cephalosporines (ceftazidime), monobactams (aztre-
onam), macrolides (azithromycin and erithromycin), tetracyclines (doxycycline, tetracycline) and quinolones 
(ciprofloxacin, levofloxacin and ofloxacin)12,28. The susceptibility of the strains to PMBN and two EPIs (NMP and 
PAβN) was also assessed.
As shown in Table 1, Ps4 susceptibility profile was compatible with overexpression of MexAB-OprM and 
resembled that of LC1-6. These results confirmed previous observations made by our group in these organisms24. 
In agreement with their MICs, RT-qPCR analysis confirmed that Ps4 and LC1-6 overexpressed mexB (Fig. 1), 
although levels of this gene transcript in the mutant LC1-6 were markedly superior. Additional RT-qPCR based 
characterization revealed that Ps4 also overproduced the cephalosporinase AmpC (Fig. 1). This fact explains in 
all likelihood the increased resistance to some β-lactams (i.e. piperacillin, ticarcillin and ceftazidime) displayed 
by Ps4 in comparison with the other strain. The relative insensitivity of PS4 to levofloxacin was probably due to 
a mutation in codon 83 of gyrA (83/(ACC:ATC)/Thr: Ile), as previously reported29. On the other hand, all the 
strains were highly resistant both to PMBN and EPIs (Table 1).
Finally, the ability of the selected strains to attach to surfaces and form biofilms was measured by using a 
microplate assay. These experiments demonstrated that LC1-6 had a very low adherent capacity, as opposed to 
Ps4 and K1119, which consistently formed very dense biofilms.
Screening of PMBN-dependent EPI potentiation on P. aeruginosa LC1-6 by the checkerboard method. 
For these planktonic cell assays, we used the strain with the highest level of MexAB-OprM overexpression, LC1-6. 
As shown in Table 2, LC1-6 showed a moderate to high level of resistance to the majority of antibiotics tested (see 
column “MIC alone”). Interestingly, concentrations as low as 1 μg/mL of both PAβN and PMBN reduced the MIC 
value of Azithromycin more than 2,000 times (i.e. from 128 μg/mL to 0.06 μg/mL). In contrast, PAβN by itself (i.e. 
without PMBN) failed to sensitize LC1-6 to Azythromycin even at the highest concentration of EPI tested (see the 
upper and leftmost panel of Supplementary Table 1a). In agreement with these results, the parameter used to quan-
tify antibiotic-enhancing activity, FICI, indicated that indeed the combination Azithromycin/PAβN/PMBN was 
extremely synergistic (FICI = 0.002; Table 2), a value much lower than that considered as the cutoff for synergism 
(FICI ≤ 0.5). These results demonstrate that a concentration as low as 1 μg/mL of PAβN causes a dramatic sensitiza-
tion of strain LC1-6 to Azythromycin in the presence of minute amounts of PMBN.
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Although the enhancement factor obtained with other antibiotics was less pronounced, the synergism among 
the three components was even more clear than that shown for Azythromycin. For instance, a combination of 
PAβN and PMBN similar as that used previously (2 and 1 μg/mL of each compound) sufficed to lower more 
than 267 times the MIC of Ceftazidime and to reach a FICI value of 0.007 (Table 2 and Supplementary Table 1a). 
Importantly, in this case none of the three double combinations that could be composed with those three com-
ponents (Ceftazidime/PAβN, Ceftazidime/PMBN and PMBN/PAβN) was close to be synergistic (FICI = 1). In 
contrast, Azithromycin acted in synergy with PMBN, although with much less potency than in the presence of the 
third component PAβN (0.01 for the double vs. 0.002 for the triple combination; Table 2). Results obtained with 
Levofloxacin and Piperacillin were very similar to those of Ceftazidime, whereas enhancement was less potent 
(16-fold reduction in MIC; FICI = 0.07) in the case of Aztreonam.
To study whether the observed potentiation could be achieved using EPIs other than PAβN, we repeated the 
assays using the structurally unrelated inhibitor NMP. As shown in the lower panel of Table 2, antibiotic activity 
was also enhanced in the presence of NMP but much less than in the case of PAβN, as reflected by significantly 
lower enhancement factors and higher FICI values (see also Supplementary Table 1b).
evaluation of selected triple combinations on P. aeruginosa Ps4 by the checkerboard method. 
The most potent triple combinations were selected and tested against the multiresistant clinical strain Ps4 using 
the checkerboard method. As mentioned before, this strain not only overexpresses MexAB-OprM but also over-
produces the cephalosporinase AmpC (Fig. 1).
Antimicrobials
MIC (μg/mL)
Ps4 LC1-6 PAO1 K1119
β-lactams
Penicillins
Piperacillin 256 (Ra) 16 (Sb) 4 (S) 0.5 (S)
Amoxicillin >512 >512 >512 >512
Ampicillin >512 >512 >512 >512
Ticarcillin 256 (R) 128 (R) 16 (S) ≤1 (S)
Cephalosporins Ceftazidime 64 (R) 4 (S) 2 (S) 4 (S)
Monobactams Aztreonam 16 (Ic) 32 (R) 32 (R) ≤1 (S)
Carbapenems
Imipenem S ndd S nd
Meropenem S R S nd
Macrolides
Azithromycin 128 128 128 32
Erithromycin 256 256 128 32
Tetracyclines
Doxycycline 64 64 4 2
Tetracycline 64 32 8 ≤1
Quinolones
Levofloxacin 16(R) 2 (S) 0.25 (S) 0.12 (S)
Ofloxacin 16 (R) 4 (I) 1 (S) 0.5 (S)
Ciprofloxacin 4 (R) ≤1 (S) ≤1 (S) ≤1 (S)
Antimicrobial Peptides PMBNe >512 >512 >512 >512
Efflux pump inhibitors
NMPf 128 64 64 64
PaβNg >512 >512 >512 >512
Table 1. Antimicrobial susceptibity of Pseudomonas aeruginosa strains used in this work. aResistant, 
bSusceptible and cIntermediate according to Clinical and Laboratory Standards Institute (CLSI) guidelines. dNot 
determined. ePolymyxin B Nonapeptide. f1-(1-naphthylmethyl)-piperazine. gL-Phe-L-Arg-β-naphthylamide 
dihydrochloride.
Figure 1. Strain LC1-6 overexpresses the gene mexB and Ps4 overexpresses the genes mexB and ampC, as 
determined by RT-qPCR. Results shown are the means ± standard deviation of three independent experiments 
where each strain was tested in triplicate wells (n = 9). The value of P. aeruginosa PAO1 was 1.
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In the absence of PMBN, the inhibitor PAβN had to be added at the highest concentration tested (16 μg/mL) to 
cause a rather modest reduction in the MIC of two antibiotics (Azithromycin and Doxycycline) (Supplementary 
Table 2). On the contrary, the addition of 1 μg/mL of PMBN together with PAβN enhanced 512 times and 128 
times the antimicrobial activity of azithromycin (from 128 to 0.25 μg/mL) and doxycycline (from 64 to 0.5 μg/
mL), respectively (Table 3). Notably, the enhancement obtained with the β-lactam antibiotics ceftazidime and 
piperacillin was of much lower level (16 times, at most), a likely consequence of AmpC overexpression in the test 
strain (Fig. 1). Despite this fact, FICIs obtained with those drugs were indicative of a good synergistic activity 
(0.07 and 0.13, respectively) suggesting that EPI may be effective in strains with a high level of expression of 
β-lactamases thereby contradicting reported claims14.
When the antibiotics were combined with NMP and PMBN, synergistic combinations were also observed 
(Table 3, Supplementary Table 2).
EPIa ABb
Antibiotic Mic (µg/mL)c Enhancement FICIe
alone +EPI + PMBNg factord AB/EPI/PMBN AB/EPI EPI/PMBN AB/PMBN
PAβNf
Azithromycin 128 0.06 (1/1) 2133 0.002 2.00 1.00 0.01
Doxycycline 64 0.12 (1/1) 533 0.004 1.00 1.00 0.25
Levofloxacin 2 0.007 (2/1) 286 0.006 1.00 1.00 0.50
Ceftazidime 4 0.015 (2/1) 267 0.007 1.00 1.00 1.00
Piperacillin 16 0.06 (2/1) 267 0.007 1.00 1.00 1.00
Aztreonam 32 2 (4/1) 16 0.07 0.51 1.00 1.00
NMPh
Azithromycin 128 0.50 (1/1) 256 0.02 1.02 1.00 0.01
Doxycycline 64 1 (1/1) 64 0.03 1.02 1.00 0.25
Levofloxacin 2 0.12 (4/1) 17 0.12 1.06 1.02 0.50
Ceftazidime 4 1 (8/1) 4 0.38 1.06 1.03 1.00
Piperacillin 16 4 (16/1) 4 0.50 1.25 1.06 1.00
Aztreonam 32 8 (16/1) 4 0.50 0.75 1.06 1.00
Table 2. Summary of synergy testing conducted on Pseudomonas aeruginosa LC1-6 by the checkerboard 
method. aEfflux pump inhibitor; bAntibiotic; cMinimum inhibitory concentration (µg/mL) of antibiotic alone 
or in combination with EPI and polymyxin B nonapeptide (the concentration of EPI and PMBN, respectively, 
present in the triple combination is shown in parenthesis); dMaximum number of times that the antibiotic MIC 
is reduced in the presence of EPI and PMBN; eFractional inhibitory concentration index of the combination 
rendering maximum enhancement and all its possible double variants (combinations were considered as 
synergistic if FICI ≤ 0.5, indifferent if 0.5< FICI ≤ 4, or antagonistic if FICI > 4) (see Material and Methods); 
fL-Phe-L-Arg-β-naphthylamide dihydrochloride; gPolymyxin B Nonapeptide; h1-(1-naphthylmethyl)-piperazine. 
Synergistic combinations are indicated in bold.
EPIa ABb
ANTIBIOTIC MIC (µg/mL)c Enhancement FICIe
alone +EPI + PMBNg factord AB/EPI/PMBN AB/EPI EPI/PMBN AB/PMBN
PAβNf
Azithromycin 128 0.25 (4/1) 512 0.01 1.00 1.00 0.50
Doxycycline 64 0.50 (4/1) 128 0.01 1.00 1.00 0.50
Ceftazidime 64 4 (8/1) 16 0.07 1.00 1.00 0.50
Piperacillin 256 32 (4/1) 8 0.13 1.00 1.00 0.50
NMPh
Azithromycin 256 4 (2/1) 64 0.03 1.01 1.06 0.25
Doxycycline 64 0.25 (1/1) 256 0.01 1.00 1.06 0.50
Ceftazidime 64 0.25 (4/1) 256 0.04 0.53 1.06 0.50
Piperacillin 256 8 (1/1) 32 0.04 0.51 1.06 0.50
Table 3. Summary of synergy testing conducted on Pseudomonas aeruginosa Ps4 by the checkerboard method. 
aEfflux pump inhibitor; bAntibiotic; cMinimum inhibitory concentration (µg/mL) of antibiotic alone or in 
combination with EPI and polymyxin B nonapeptide (the concentration of EPI and PMBN, respectively, 
present in the triple combination is shown in parenthesis); dMaximum number of times that the antibiotic MIC 
is reduced in the presence of EPI and PMBN; eFractional inhibitory concentration index of the combination 
rendering maximum enhancement and all its possible double variants (combinations were considered as 
synergistic if FICI ≤ 0.5, indifferent if 0.5 < FICI ≤ 4, or antagonistic if FICI > 4) (see Material and Methods); 
fL-Phe-L-Arg-β-naphthylamide dihydrochloride; gPolymyxin B Nonapeptide; h1-(1-naphthylmethyl)-piperazine. 
Synergistic combinations are indicated in bold.
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Although all the triple combinations tested were found to be synergistic (Table 3), the FICIs obtained in Ps4 
with PAβN were approximately an order of magnitude higher (i.e less potent) than the equivalent ones measured 
in LC1-6. In contrast, the FICIs obtained in Ps4 with NMP were more potent than the ones determined in LC1-
6. As previously shown with LC1-6, PAβN and NPM synergized in strain Ps4 neither with antibiotics nor with 
PMBN (see columns AB/PAβN and PAβN/PMBN in Table 3). However, in this strain, PMBN slightly synergized 
with all the antibiotics in the absence of the EPI, although the triple combinations improved notably (from 4 to 50 
times) the FICI values of the double ones in all the cases.
evaluation of selected triple combinations on P. aeruginosa K1119 by the checkerboard method. 
The most potent triple combinations were also tested in K1119, a mexAB-oprM deletion mutant. As somewhat 
expected in a mutant lacking one of the major efflux pumps, exposure to PAβN even at the highest concen-
trations had no effect on K1119 antibiotic susceptibility (Supplementary Table 3a). In contrast, the other EPI, 
NMP, showed a significant antibiotic enhancing activity by itself when added at medium to high concentrations 
(Supplementary Table 3b).
Apart from the Doxyxycline/PMBN and Piperacillin/NMP combinations, none of the other double combina-
tions were synergistic (Table 4). The FICI values obtained with the triple combinations paralleled the lowest FICIs 
obtained with the double combinations and were not improved by addition of a triple component except for the 
azithromycin/PMBN/NMP triple combination (Table 4, Supplementary Table 3).
evaluation of selected triple combinations on P. aeruginosa PAO1 by the checkerboard method. 
The most potent triple combinations were also tested in PAO1, a strain expressing wild type levels of 
MexAB-OprM. In contrast to K1119, the PAβN inhibiting effect was clearly detectable in PAO1 with the three 
tested antibiotics (Supplementary Table 4a). NMP was also able to enhance antibiotic activity in the absence 
of AMP. Azythromycin and Doxycycline synergized with EPIs and PMBN. However, this enhancement can be 
attributed in its totality to the synergistic activity detected between the antibiotics and the AMP. On the other 
hand, the synergism observed between piperacillin, PMBN and both EPIs was higher than any of the other pos-
sible double combinations (Table 5, Supplementary Table 4).
Kinetics of inhibition of P. aeruginosa Ps4 by triple combinations. To further discriminate the con-
tribution of each component of the combination to the global antimicrobial activity observed, growth inhibition 
assays were performed using the automated optical analyzer Bioscreen C. For these assays, we selected the com-
bination that displayed the highest potency against the two MexAB-OprM overexpressing strains, namely azith-
romycin/PAβN/PMBN. As shown in Fig. 2a, this combination was the only one capable of completely inhibiting 
the growth of Ps4 during the first 15 h. The removal of any compound from that combination resulted in a signif-
icant loss of the inhibitory capacity. To quantify the growth inhibition due to each treatment we determined the 
corresponding area under the curve (AUC). In agreement with previous results, comparison of the AUCs of the 
different treatments revealed that only the triple combination azithromycin/PAβN/PMBN could inhibit in a very 
significant way (**p < 0.01) the growth of Ps4 (Fig. 2b). Taken together, these results demonstrate that a perme-
abilizing agent at subinhibitory concentrations can synergize with EPIs and sensitize efflux pump overexpressing 
strains of P. aeruginosa to antibiotics substrates of those EPIs.
Enhancement of EPIs by PMBN in biofilms of P. aeruginosa Ps4 grown in the CDC biofilm reactor. 
Previously, we showed that Ps4 could form biofilms under static growth conditions in microplates. However, to 
try to mimic in vivo conditions we also confirmed that this strain could also form biofilms when exposed to a 
turbulent flow in the CDC reactor. In this device, the biofilm develops on the surface of small disks called cou-
pons that are constantly bathed in fresh culture medium. Biofilm formation was assessed by fluorescence and 
EPIa ABb
ANTIBIOTIC MICc (µg/mL) Enhancement 
factord
FICIe
alone +EPI + PMBNg AB/EPI/PMBN AB/EPI EPI/PMBN AB/PMBN
PAβNf
Azithromycin 32 16(1/1) 2 0.502 1.001 1 0.501
Doxycycline 2 0.125 (1/1) 16 0.064 1.016 1 0.063
Piperacillin 0.5 0.5 (1/1) 1 1.002 1.016 1 1.001
NMPh
Azithromycin 32 0.03(4/1) 1066 0.064 0.563 1.06 0.501
Doxycycline 2 0.06 (2/1) 32 0.063 1.031 1.06 0.063
Piperacillin 0.5 0.03 (8/1) 16 0.188 0.188 1.06 1.001
Table 4. Summary of synergy testing conducted on Pseudomonas aeruginosa K1119 by the checkerboard  
method. aEfflux pump inhibitor; bAntibiotic; cMinimum inhibitory concentration (µg/mL) of antibiotic alone  
or in combination with EPI and polymyxin B nonapeptide (the concentration of EPI and PMBN, respectively, 
present in the triple combination is shown in parenthesis); dMaximum number of times that the antibiotic MIC 
is reduced in the presence of EPI and PMBN; eFractional inhibitory concentration index of the combination 
rendering maximum enhancement and all its possible double variants (combinations were considered as 
synergistic if FICI ≤ 0.5, indifferent if 0.5 < FICI ≤ 4, or antagonistic if FICI > 4) (see Material and Methods); 
fL-Phe-L-Arg-β-naphthylamide dihydrochloride; gPolymyxin B Nonapeptide; h1-(1-naphthylmethyl)-piperazine. 
Synergistic combinations are indicated in bold.
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confocal microscopy on coupons stained with the LIVE/DEAD BacLight kit. Analysis of the surface or cryosec-
tions of coupons grown under these conditions revealed the characteristic morphology of biofilms with abundant 
finger-like projections protruding from the surface. (Fig. 3)
EPIa ABb
ANTIBIOTIC MICc (µg/mL) Enhancement 
factord
FICIe
alone +EPI + PMBNg AB/EPI/PMBN AB/EPI EPI/PMBN AB/PMBN
PAβNf
Azithromycin 256 4 (1/1) 64 0.018 1.001 1 0.017
Doxycycline 4 0.03 (1/1) 133 0.01 1.001 1 0.009
Piperacillin 4 0.5 (1/1) 8 0.127 0.516 1 0.251
NMPh
Azithromycin 256 4 (1/1) 64 0.032 1.016 1.06 0.017
Doxycycline 4 0.03 (1/1) 133 0.024 1.016 1.06 0.009
Piperacillin 4 0.06 (2/1) 63 0.048 1.031 1.06 0.251
Table 5. Summary of synergy testing conducted on Pseudomonas aeruginosa PAO1 by the checkerboard 
method. aEfflux pump inhibitor; bAntibiotic; cMinimum inhibitory concentration (µg/mL) of antibiotic alone 
or in combination with EPI and polymyxin B nonapeptide (the concentration of EPI and PMBN, respectively, 
present in the triple combination is shown in parenthesis); dMaximum number of times that the antibiotic MIC 
is reduced in the presence of EPI and PMBN; eFractional inhibitory concentration index of the combination 
rendering maximum enhancement and all its possible double variants (combinations were considered as 
synergistic if FICI ≤ 0.5, indifferent if 0.5 < FICI ≤ 4, or antagonistic if FICI > 4) (see Material and Methods); 
fL-Phe-L-Arg-β-naphthylamide dihydrochloride; gPolymyxin B Nonapeptide; h1-(1-naphthylmethyl)-piperazine. 
Synergistic combinations are indicated in bold.
Figure 2. PMBN sensitizes a MexAB-OprM overexpressing Pseudomonas aeruginosa clinical strain (Ps4) to 
PAβN and an antibiotic substrate of MexAB-OprM (azithromycin), as determined by turbidimetry (Bioscreen 
C). (a) At time 0, cultures were exposed to the indicated antimicrobial combinations and incubated with 
shaking at 37 °C in an optical analyzer that automatically monitors optical density at regular intervals. The 
inoculum and the culture medium (MHCA) were the same as those used to determine the MIC. AZM: 
azithromycin (0.25 μg/mL); PAβN: L-Phe-L-Arg-β-naphthylamide (4 μg/mL); PMBN (1 μg/mL). (b) Area 
under the curve during the first 45 h of growth of indicated cultures (panel (a)). Results shown are the 
means ± standard deviation of three independent experiments where each concentration was tested in triplicate 
wells (n = 9). Data were analyzed using Kruskal Wallis test with multiple comparisons and statistical differences 
between the culture treated with the triple combination and the untreated control were very significant 
(**p = 0.0077). Alpha = 0.05.
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To study if PMBN-mediated enhancement of EPI was also efficient against P. aeruginosa biofilms we treated 
coupons with the selected triple combination at 50 times its planktonic MIC (i.e. Azithromycin (12.5 μg/mL), 
PAβN (200 μg/mL) and PMBN (50 μg/mL)). In theory, Azithromycin is particularly well-suited for anti-biofilm 
therapy because it has been reported to interfere with the quorum sensing signals mediated by lasI.6,30–33. As 
shown in Fig. 4, the selected combination reduced in a significant way (*p < 0.05) bacterial viability (7.5 log-
arithms) of a 48h-old biofilm, although the positive control of bactericidal activity (chlorine at 1,000 μg/mL) 
showed more potent activity. Similar to our observations with planktonic cells of Ps4, removal of any component 
of the combination significantly decreased its anti-biofilm activity.
Our results indicate that, at 50 times its planktonic MIC, the experimental combination reduces more than 
10,000,000 times the viability of mature biofilms formed by Ps4 and that EPI enhancement by PMBN seems to 
play a role in this bactericidal activity.
Discussion
In the present study, we have demonstrated for the first time that a permeabilizing agent at subinhinbitory con-
centrations is able to sensitize strains that overexpress MexAB-OprM to a combination of a substrate antibiotic 
and an EPI, being the combination unsuccessful in the absence of the permeabilizing agent.
Specifically, we found that at subinhibitory concentrations, PMBN-mediated potentiation of PAβN resulted 
in sensitization to antibiotics by factors of up to 2,133 in the mutant strain P. aeruginosa LC1-6 (Table 2; 
Supplementary Table 1a). The activity of the inhibitor NMP in combination with antibiotics was also enhanced 
by PMBN (Table 2; Supplementary Table 1b), but to a lesser extent than when PAβN was used in that same strain. 
This observation is in agreement with previous reports showing that PAβN has more efflux pump inhibiting 
potency than NMP15,34,35. Accordingly, the maximum enhancement achieved by NMP was of 256 times when 
this EPI was combined with Azithromycin (from 128 μg/mL to 0.5 μg/mL; FICImin = 0.02). It is important to 
note that the level of enhancement achieved by PMBN with the antibiotics Azithromycin and Doxycycline was 
higher than with the other antibiotics (i.e. in the absence of the EPI; first rows of Supplementary Table 1a,b), and 
this correlated with the potency of the sensitization obtained with each triple combination. This fact reflects in 
all likelihood the mechanism used by each antibiotic to cross the outer membrane of P. aeruginosa, namely the 
lipid-mediated pathway for azithromycin and doxycycline and the porin-mediated for the rest36. As a conse-
quence, antimicrobials using the former pathway heavily rely on permeabilization by PMBN to gain access to 
their intracelullar target, whereas those of the second group had a much lower dependence of this mechanism 
(Tables 2–5). Nevertheless, our results demonstrate that all triple combinations when tested in the MexAB-OprM 
overexpressing strains LC1-6 and Ps4, strictly depend on EPIs to achieve their maximum sensitization level. On 
the other hand, when the test strains do not overexpress MexAB-OprM, such as in PAO1 or K1119, the observed 
synergistic activity can be attributed to either the antibiotic/PMBN or antibiotic/EPI combination.
Figure 3. When grown under turbulent conditions in the CDC reactor, Pseudomonas aeruginosa Ps4 forms 
dense biofilms that stain green with the LIVE/DEAD BacLight kit. (a) Cryosectioning fluorescence microscope 
image taken at 20x magnification. (b) Top view at low magnification (10x; fluorescence microscopy) of the 
surface of a coupon coated with a biofilm layer. (c) Confocal laser scanning microscope image of the coupon 
surface at 1.5x magnification, Scale bars length is 100 μm in (a) and (b) and 1000 μm in (c).
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The higher expression of mexAB-oprM in LC1-6 compared to Ps4 might explain why NMP is more potent in 
the latter strain.
The observed Antibiotic/NMP synergistic activity in the strain K1119 (Table 4; Supplementary Table 3b) 
seems to indicate a hypothetic NMP activity in other efflux pumps different from MexAB-OprM whose expres-
sion might be induced by antibiotic exposure (Supplementary Table 3). This activity would go unnoticed in the 
strain LC1-6 because NMP concentration would be insufficient to inhibit the elevated MexAB-OprM levels 
expressed by this strain (Supplementary Table 1).
In addition to its inhibitory action, it has been reported that PAβN acts as a weak permeabilizer when used at 
sufficiently high concentrations (20 μg/mL), whereas its EPI activity is observable at much lower concentrations 
(1,25 μg/mL)37,38. In contrast, the other EPI used in our assays, NMP, has no reported permeabilizing activity. 
Since PAβN synergized with antibiotics in our assays at concentrations as low as 1 μg/mL, this activity results in 
all likelihood from the inhibition of efflux pumps. In agreement with this, enhancement of antibiotic activity by 
the other EPI, NMP, was also detected at low concentrations (1–4 μg/mL).
In the presence of the inhibitor PAβN, the triple combinations exhibited a loss of activity at concentrations 
higher than or equal to 4–8 μg/mL of the EPI (Supplementary Table 1a). This might be due to aggregation of 
PAβN, which is strongly cationic at neutral pH and could be displaced by other cations (Mg2+ and Ca2+ present in 
culture medium) or by the polycationic agent PMBN14. In contrast, this saturation effect was not observed when 
using the inhibitor NMP (Supplementary Table 1b), which has much less cationic character39. Nevertheless, no 
solubility problems (e.g. the presence of insoluble precipitates) were detected during the course of this study. 
Alternatively, this loss of activity could be due to an Eagle effect of PAβN. The phenomenon has been described as 
a paradoxical effect of drugs where more drug kills less and apparently is not related to solubility40,41.
In addition, we showed that the potentiation of EPIs by PMBN caused a 10 million-fold reduction in biofilm 
viability in a multidrug clinical isolate of Pseudomonas. In agreement with this conclusion, other authors reported 
that efflux pumps are highly active in young (<4 day-old) bacterial biofilms10,42, like ours and MexCD-OprJ, 
MexAB-OprM and a novel ABC transporter of P. aeruginosa were shown to be involved in biofilm resistance to 
Azithromycin9–11. Besides, there is evidence supporting that biofilms are susceptible to antibiotic sensitization 
by permeabilizers of different nature including farnesol43, EDTA44, cholic acid45, HAMLET46, terpenoids47 and 
antimicrobial peptides48. However, our data do not allow us to conclude whether the reported permeabilizing 
activity of PAβN at concentrations above 20 μg/mL37, could contribute to the anti-biofilm activity shown here. 
Figure 4. The three components of the triple combination (antibiotic/EPI/PMBN) are necessary to reduce 
the number of biofilm cells of Pseudomonas aeruginosa Ps4 grown in the CDC biofilm reactor. After 24 h of 
incubation under continuous flow, coupons coated with 48 h mature biofilms were removed from the reactor, 
washed and exposed at 37 °C for 72 h (with renewal of the solution every 24 h) to either a positive control 
of bactericidal activity (chlorine 1,000 μg/mL), a standard treatment for Gram-negative biofilm eradication 
(ceftazidime 5,000 μg/mL) or the indicated antimicrobial combinations at 50 times their planktonic MIC in 
phosphate buffer (planktonic MIC = AZM (0.25 μg/mL); PAβN (4 μg/mL); PMBN (1 μg/mL)). Then, biofilms 
were detached from coupons by using mechanical means, homogenized by sonication and viable bacteria were 
enumerated by colony counting. Finally, the logarithmic reduction of viable cells caused by each treatment was 
calculated using untreated coupons as reference controls of viability. AZM: Azithromycin; PAβN: L-Phe-L-Arg-
β-naphthylamide; PMBN: Polymyxin B nonapeptide. Results shown are the means ± standard deviation of two 
independent experiments where each condition was tested in duplicate coupons (n = 4). Differences between 
treatments were analized with a One-Way-ANOVA followed by Tukey’s multiple comparison test. Differences 
were highly significant for the positive control (***p = 0.0002) or significant for the triple combination 
(*p = 0.0156) compared to the untreated control. Alpha = 0.05.
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Furthermore, we cannot rule out that the reduction in viability observed in our assays could be due, not to bacte-
ricidal activity, but to a hypothetical ability of the triple combination to remove biofilm from the coupon surface.
Notably, under our experimental conditions, a treatment frequently used to kill Gram-negative bacterial 
biofilms colonizing indwelling devices such as catheters (ceftazidime 5000 μg/mL) had an almost negligible 
anti-biofilm effect (Fig. 4)49. This suggests that the experimental combination developed in this work could find 
application in antibiotic lock therapy (ALT), a strategy aimed at eradicating biofilms formed in the lumen of cen-
tral venous catheters to salvage these devices and avoid their removal49.
The significant toxicity of currently available EPIs has prevented the clinical use of these drugs15. In this 
respect, our results have important implications because we demonstrated that EPI activity can be dramatically 
enhanced by a permeabilizing molecule and that this potentiation reduces the amount of inhibitor needed to 
sensitize P. aeruginosa to values as low as 1 μg/mL (Tables 2 and 3). However, experimentation in animal models 
is required to study whether our strategy has therapeutic potential.
Nevertheless, toxicity of current EPIs should not hinder their use in ALT, since the drugs used in this pro-
cedure never get into the bloodstream. Interestingly, in the present work, biofilms were exposed to the triple 
combination for 72 h, whereas ALT solutions are applied for 10–14 days49. Furthermore, antibiotic concentrations 
in ALT solutions are normally adjusted to 1,000 times their planktonic MICs49, whereas in our experiments we 
used a much lower concentration of each agent (i.e. 20 times lower than that value). Thus, the anti-biofilm activity 
displayed by our experimental therapy is expected to be of much higher magnitude when used for ALT.
Material and Methods
Culture conditions and susceptibility testing. The P. aeruginosa strains used in this study were the 
wild type PAO1, the clinical strain Ps4, the MexAB-OprM overexpressing mutant LC1-6 and the PAO1 derivate 
with a deletion in the efflux pump MexAB-OprM that abrogates its activity K111924,26,27. For routine procedures, 
bacteria were grown at 37 °C in Tryptic Soy Broth (TSB; BioMerieux) or in TSB supplemented with 16 g/L agar 
(TSA; Pronadisa, Spain). TSB was also used as medium for biofilm growth. For planktonic cultures, MICs of anti-
microbials were determined in Mueller-Hinton cation adjusted (MHCA) broth (Difco Laboratories) using serial 
twofold dilutions according to CLSI guidelines50, as detailed previously24. Antimicrobials with MICs higher than 
the maximum concentration tested were assigned a MIC twice that concentration. MHCA broth was also used 
for synergy testing (checkerboard assay), growth inhibition experiments (see below) and to test the bactericidal 
effect of the antimicrobials on biofilm cells.
Antimicrobial agents. PMBN, Amoxicillin, Ampicillin, Aztreonam, Ceftazidime, Ciprofloxacin, 
Doxycycline, Erithromycin, Levofloxacin, Ofloxacin, Piperacillin, Tetracycline, Ticarcillin, PAβN and NMP were 
purchased from Sigma-Aldrich. Azythromycin was obtained from Pfizer (Zithromax® intravenous solution; 
Viena, Austria). Stock solutions at 10 mg/mL were dissolved as detailed in Supplementary Table 5, according to 
manufacturer’s recommendations. Then, they were diluted in water and then during the synergy testing, they 
were further diluted in MHCA.
Real Time quantitative PCR (RT q-PCR). The expression of the genes mexB and ampC was quan-
tified by RT q-PCR according to previously described protocols51. Briefly, mid-log phase bacterial cultures in 
Luria-Bertani broth were collected and total RNA was extracted with the RNeasy Mini kit (Qiagen), treated 
with DNase (DNA-free DNase Treatment; Ambion), and 0.8 μg were retrotranscripted with the SuperScript 
kit III (Invitrogen). The cDNA of the gene mexB was relatively quantified by RT-qPCR with the SYBR Green 
PCR Master Mix (Applied Biosystems) following manufacturer’s recommendations and referred to the 
housekeeping gene proC and the reference strain PAO1. The primers used for mexB amplification were for-
ward 5′-TTGATAAGGCCCATTTTCGCGT-3′ and reverse 5′-TCTGCTGCTCGATCACCTGGA-3′ with a 
product size of 310 bp, for proC amplification, forward 5′-CAGGCCGGGCAGTTGCTGTC-3′ and reverse 
5′-GGTCAGGCGCGAGGCTGTCT-3′ with a product size of 188 bp and for ampC amplification forward 
5′-GGCGACATGACAGGGCCT-3′ and reverse 3′-TCCAGGCCGCTGAGGATGGC-5′ with a product size of 
296 bp. A relative expression of the genes mexB and ampC greater than or equal to 3 or 10 respectively, was con-
sidered overexpression, as described by Cabot et al.51. The experiment was repeated independently at least three 
times.
Two and three-dimensional synergy testing. Potential synergistic interactions between two antimi-
crobials were assessed by the checkerboard assay using MHCA broth as described before25. To quantify syner-
gistic interactions between three antimicrobials a three dimensional checkerboard test was used52. For the latter 
method, the checkerboard assay was performed in the presence of a fixed concentration of one of the antimicro-
bials. Briefly, a fresh culture of P. aeruginosa Ps4, K1119, PAO1 or LC1-6 was adjusted to 0.5 McFarland stand-
ard (equivalent to 108 CFU/mL) and diluted 1:100 with MHCA to obtain a 106 CFU/mL suspension. Aliquots 
of 100 μL of this suspension were transferred into the wells of a standard microtiter plate and mixed with an 
equal volume of antimicrobial solution. For each strain, the antibiotic concentration range was selected accord-
ing to previously determined MICs. In total, 10 different concentrations of the selected antibiotic (Aztreonam, 
Azithromycin, Ceftazidime, Doxycycline, Levofloxacin or Piperacillin) were combined with 5 different concen-
trations of the EPI (NMP or PAβN) maintaining PMBN concentration. The concentration of PMBN was adjusted 
to 1 μg/mL, since preliminary experiments showed that this was the minimum amount of enhancer needed to 
potentiate the majority of antibiotics in the absence of EPI. Microplates were incubated at 37 °C and growth in the 
wells was visually assessed after 18–20 h. Each assay included growth control wells containing inoculated medium 
without antimicrobials and sterility control wells consisting of uninoculated medium. The fractional inhibitory 
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FICIs were calculated with the concentrations in the first non-turbid well found in each row and column of the 
microplate. Combinations were classified as synergistic (FICI ≤ 0.5), indifferent (0.5 < FICI ≤ 4), and antagonistic 
(FICI > 4).
Growth inhibition curves. Kinetics of inhibition of planktonic bacteria by selected antimicrobial combina-
tions was measured in the automated optical analyzer Bioscreen C (Labsystems Laboratories, Helsinki, Finland) 
in MHCA broth. Bioscreen C monitors the turbidity of bacterial cultures growing in 100-well honeycomb plates 
at regular intervals. A cell suspension from an overnight culture of Ps4 was first adjusted to OD600nm = 0.040 
and then diluted 100 times in the same broth and mixed with the different treatments under study (two and 
three-component combinations, as well as each antimicrobial alone). Microplate wells were filled with 200 μL of 
the test suspensions and incubation was carried out at 37 °C for 48 hours with continuous shaking and monitor-
ing the absorbance every 15 minutes at 420–580 nm. Each experiment was independently repeated three times 
and each concentration was tested in three wells. The inhibitory activity of different treatments was compared by 
determining the corresponding area under the curve (AUC) during the first 45 h of incubation and by applying 
the Mann Whitney U Test complemented with Kruskal Wallis comparisons (*p < 0.05).
Biofilm formation and assessment of anti-biofilm activity. The ability to form biofilm under static 
conditions in microtiter plates was assessed as described previously54.
Biofilms of Ps4 were also grown under dynamic shear conditions using the CDC-reactor (model CBR 90–1, 
BioSurface Technologies Corporation, Bozeman, MT. USA) as described elsewhere55. Briefly, a dense biofilm 
(1 × 1012 CFU/cm2, approximately) was developed on the surface of small disks called coupons that were con-
stantly bathed in fresh TSB medium. After 24 h of incubation under continuous flow, coupons were removed from 
the chamber and planktonic cells were eliminated by rinsing them with phosphate buffer (625 μM KH2PO4, 2 mM 
MgCl2∙6H2O, pH 7.2). Then, the coupons with 48 h mature biofilms attached to their surface were immersed in 
and treated with 1.75 mL of phosphate buffer, containing either a positive control of bactericidal activity (chlorine 
1,000 μg/mL), a standard treatment for Gram-negative biofilms (ceftazidime 5,000 μg/mL)49 or different combi-
nations of the antimicrobials at 50 times their planktonic MIC. Finally, coupons were incubated at 37 °C for 72 h 
with renewal of the solution every 24 h and then they were rinsed with phosphate buffer and processed for colony 
counting.
For the colony counting method, biofilms were detached by scraping the coupon surface with a sterile wooden 
stick. Then, biofilm cells were suspended in phosphate buffer, samples were homogenized by sonication for 5 min 
(Fungilab US1′6; Spain) and aliquots were plated for counting. These count values were used to calculate the so 
called, log density of the coupon which corresponds to the CFU/cm2 of biofilm cells attached to the coupon. In 
turn, log density allowed the determination of log10 reduction, which was defined as the difference of log density 
between the untreated and the treated biofilm. Experiments were independently repeated twice in duplicate cou-
pons and differences between treated and not treated coupons were analyzed by one-way ANOVA followed by 
Tukey’s multiple comparison test (*p < 0.05).
For the microscopic assessment of biofilm formation, biofilms grown on coupons were first stained with the 
LIVE/DEAD BacLight kit (Life Technologies) following the manufacturer’s recommendations. Then, the coupon 
surface was examined with a Nikon Eclipse E800 fluorescence microscope using the FITC and TRITC filters 
and the 10x or 20x objectives. Alternatively, microscopic images were taken by confocal laser microscopy (Leica 
TCS-SP5) using a 1.5x objective and Imaris® software (Bitplane, Switzerland)55. Finally, 5 μm thick cryosections 
(Leica CM1850 cryostat) were obtained as previously described and examined by fluorescence microscopy as 
mentioned above56.
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